Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Bennett

Showing results (61-70 of 331) with videos related to

Pageof 34
Sort By:
Cancer Treatment and Research|November 30, 2022
Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year UpdateCharles L Bennett, Bartlett Witherspoon, Kenneth R Carson
JAMA|November 11, 2010
Screening colonoscopy vs flexible sigmoidoscopySudha Xirasagar, Charles L Bennett, James R Hebert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
Reply to A.M. Zeidan et alJohn Bian, LeAnn B Norris, Charles L Bennett
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaBenjamin Djulbegovic, LeAnn B Norris, Charles L Bennett
Urology|January 2, 2019
EDITORIAL COMMENTZaina P Qureshi, Simon Kim, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?Jared R Adams, Cara Angelotta, Charles L Bennett
JAMA Oncology|May 26, 2018
Thalidomide, Drug Safety, and Off-label Prescribing: Lessons Learned From Celgene's SettlementY Tony Yang, Brian Chen, Charles L Bennett
Urology|April 1, 2014
Editorial commentSandip M Prasad, Oliver Sartor, Charles L Bennett
The American Journal of Medicine|April 30, 2017
Why California's Proposition 61 Was a Bad IdeaY Tony Yang, Brian Chen, Charles L Bennett
JAMA Oncology|January 4, 2024
Addressing the Drug-Shortage Crisis in OncologyY Tony Yang, Mariana Socal, Charles L Bennett
Pageof 34

Showing results (61-70 of 331) with videos related to

Sort By:
Pageof 34
Cancer Treatment and Research|November 30, 2022
Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year UpdateCharles L Bennett, Bartlett Witherspoon, Kenneth R Carson
JAMA|November 11, 2010
Screening colonoscopy vs flexible sigmoidoscopySudha Xirasagar, Charles L Bennett, James R Hebert
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2017
Reply to A.M. Zeidan et alJohn Bian, LeAnn B Norris, Charles L Bennett
The New England Journal of Medicine|July 19, 2013
Colony-stimulating factors for febrile neutropeniaBenjamin Djulbegovic, LeAnn B Norris, Charles L Bennett
Urology|January 2, 2019
EDITORIAL COMMENTZaina P Qureshi, Simon Kim, Charles L Bennett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?Jared R Adams, Cara Angelotta, Charles L Bennett
JAMA Oncology|May 26, 2018
Thalidomide, Drug Safety, and Off-label Prescribing: Lessons Learned From Celgene's SettlementY Tony Yang, Brian Chen, Charles L Bennett
Urology|April 1, 2014
Editorial commentSandip M Prasad, Oliver Sartor, Charles L Bennett
The American Journal of Medicine|April 30, 2017
Why California's Proposition 61 Was a Bad IdeaY Tony Yang, Brian Chen, Charles L Bennett
JAMA Oncology|January 4, 2024
Addressing the Drug-Shortage Crisis in OncologyY Tony Yang, Mariana Socal, Charles L Bennett
Pageof 34